• Patients voluntarily participated in the study and signed informed consent;

• Age ≥60 years old, gender unlimited;

• ECOG PS ≤2;

• Expected survival ≥6 months;

• A definitive diagnosis of ITP, including newly diagnosed, chronic, and persistent ITP;

• PLT \< 30×109/L for at least two consecutive times with an interval of at least 1 day before medication

• Patients with laboratory test results meet the following criteria: a. alanine aminotransferase (ALT) 3.0 x or less normal limit (ULN), aspartate aminotransferase (AST) 3.0 x ULN or less; b. Serum total bilirubin ≤1.5×ULN; c. Serum creatinine ≤1.5×ULN;

• The researchers determined that patients could be treated with hexapopal.